Navigation Links
Champions Biotechnology Reports Fiscal 2010 Third Quarter Financial Results
Date:3/17/2010

">David Sidransky, Chairman of the Board of Directors of Champions Biotechnology, Inc., commented, "This past quarter, although we saw reduced revenues from our Personalized Oncology business, we continued to see solid performance from our Preclinical eValuation business. Having made strong progress in building the integrity of our platform for the Preclinical eValuation business, we can now more fully implement our primary objective to in-license a pipeline of high potential oncology drugs and compounds. The Company progress to date is evidenced by the following:

  1. The Company's quarterly Preclinical eValuation revenues increased 402% year over year.
  2. Champions entered into an exclusive Option Agreement with a leading Canadian research organization to review a cancer drug candidate.  This brings our total number of products owned, licensed or under option agreements to four.
  3. Champion's Preclinical eValuation business expanded and initiated new contracts with several major Biotechnology and Pharmaceutical companies.
  4. Champions has received signed subscription agreements totaling $3.0 million to date of which $2.2 million has been received in our private placement to accredited investors."

For more information regarding Champions Biotechnology's business and recent news, please visit www.championsbiotechnology.com


'/>"/>
SOURCE Champions Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Dr. David Sidransky Appointed Chairman of Champions Biotechnology, Inc.
2. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
3. Champions Biotechnology, Inc. Appoints New Board Members and Forms Management Team
4. Champions Biotechnology, Inc. Completes $2,500,000 Private Financing at $1.75 per Share
5. Champions Biotechnology and ImClone Systems Establish Agreement for Preclinical Evaluation of Oncology Drugs
6. Champions Biotechnology Reports Fiscal 2008 Full-Year Financial Results
7. Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
8. Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business
9. Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing
10. Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
11. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... According to a new market report ... Transgenic Crops (Corn, Soybean, Cotton and Others), Synthetic Biology-Enabled ... Growth, Trends and Forecast, 2013 – 2019,”the global agricultural ... 2012 and is expected to reach USD 28,694.1 million ... 2013 to 2019. , Demand for food production ...
(Date:2/26/2015)... 2015 Regis Technologies announced new ... oncology drug substances. , Regis Technologies is proud to ... Potent Compound Suite (PCS) for 2015. , Regis is ... cGMP facility in Morton Grove, Illinois. The PCS addition ... compounds up to about one kilogram per batch. ...
(Date:2/26/2015)... , Feb. 26, 2015 Tauriga Sciences, ... sciences company with interests in the natural wellness sector ... announced today that its products will be featured at ... Capital Partners, 27 th Annual Growth Stock Conference ... located at 1 Ritz Carlton Drive, Dana ...
(Date:2/26/2015)...   Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ... Cowen 35 th Annual Health Care Conference on Tuesday, ... Boston .  Lexicon management will provide an overview of ... of the presentation will be available through Lexicon,s website at ... be available at www.lexpharma.com until April 3, 2015. ...
Breaking Biology Technology:Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 2Global Agricultural Biotechnology Market is Expected to Reach USD 28,694.1 Million in 2019 : Transparency Market Research 3Regis Extends cGMP Services to Oncology Market 2SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 2SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 3SEC Compliance Featuring Products From Tauriga Sciences, Inc. at ROTH Capital Conference 4Lexicon To Present At The Cowen 35th Annual Health Care Conference 2
... Company, FRAZER, Pa., Feb. 8 Cephalon, Inc., ... Counsel &,Secretary, John E. Osborn, has decided to resign ... has agreed to remain as an advisor,to the company ... been an invaluable member of our senior executive team ...
... REDWOOD CITY, Calif., Feb. 8 Genomic Health,Inc. (Nasdaq: ... Health,s,President and Chief Operations Officer, will present at the ... Feb. 12, 2008 at 10:15 a.m. Eastern,Time., To ... visit the Investor Relations section of Genomic Health,s,website at ...
... InterMune, Inc.,(Nasdaq: ITMN ) today announced results from operations ... company also provided 2008,financial guidance and milestones for its key ... InterMune reported a net loss for the fourth quarter of ... net loss of $21.5 million, or,$0.64 per share, in the ...
Cached Biology Technology:Cephalon General Counsel John E. Osborn to Resign Position 2Cephalon General Counsel John E. Osborn to Resign Position 3InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 2InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 3InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 4InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 5InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 6InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 7InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 8InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 9InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 10InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance 11
(Date:2/9/2015)... RICHARDSON, Texas , Feb. 9, 2015  Lintec ... novel fabrication methods for carbon nanotube (CNT) macrostructures, including ... Texas at Dallas (UTD). Leveraging the vast ... Tokyo, Japan , Lintec of America ... Richardson, TX , focusing on scaling ...
(Date:2/5/2015)... SAN DIEGO , Jan. 26, 2015   Epic ... treatment of cancer, today announced that Murali Prahalad , ... Personalized Medicine World Conference (PMWC) 2015: Silicon Valley, ... Mountain View, Calif. on January 26-28, ... entitled, "CTCs Come of Age as Biomarkers." Last year, Epic ...
(Date:2/5/2015)... -- New Market Research Reports Title Global ... 2020 has Been Added to GrandViewReseach.com Report Database ... reach USD 5.10 billion by 2020, according to a ... help identify the site of tissue damage in case ... in medical imaging applications. They have been extensively used ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... date of 130 North American tree species concludes that ... northward by hundreds of kilometers and shrink the ranges ... McKenney of the Canadian Forest Service and his colleagues, ... McKenneys study is based on an extensive data-gathering effort ...
... Trust researchers have identified a key gene involved in the ... mostly women. The lead researcher behind the study has called ... to further study the underlying causes of the disease. ... autoimmune disease which frequently causes skin rash, joint pains and ...
... able to differentiate metastatic cancer cells from normal cells ... softness of the cells. The study, published Dec. ... journal Nature Nanotechnology, represents one of the first times ... cancer patients and apply nanotechnology to analyze them and ...
Cached Biology News:Climate change predicted to drive trees northward 2Lupus gene finding prompts call for more DNA samples 2Using nanotechnology, UCLA researchers discover cancer cells 'feel' much softer than normal cells 2Using nanotechnology, UCLA researchers discover cancer cells 'feel' much softer than normal cells 3Using nanotechnology, UCLA researchers discover cancer cells 'feel' much softer than normal cells 4
Identify and characterize Phosphoinositide (PI(3,4,5)P3) binding...
Anti-Human alpha2-Antiplasmin Purified (Polyclonal) (goat IgG)...
Volume adapter mounts on top of the 96 well FiltrEX filter plate and allows larger volumes (1mL) to be applied to each well in a filter plate. Adapters are nonsterile....
... The Mini-PROTEAN 3 Dodeca cell with multi-casting chamber ... up to 12 mini format handcast (8.3 x ... gels. The cell requires 3.4-4.4 L of buffer ... coil that attaches to an external refrigerated circulator ...
Biology Products: